echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > COVID-19 candidate vaccine LUNAR®-COV19: Preclinical studies confirmed effectiveness

    COVID-19 candidate vaccine LUNAR®-COV19: Preclinical studies confirmed effectiveness

    • Last Update: 2020-11-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Text . . The immune response mediated by simba LUNAR®-COV19 (ARCT-021) produces a strong viral antigen-specific CD8-T lymphocyte response and Th1 explicit immune response.
    Pharmaceuticals announced that the data was available on Bioarchive's online preprint server and was undergoing a scientific peer review.
    it conducted an in-depth assessment of the immune activation of body fluids and cell-mediated after a single dose of the vaccine in mice, and showed that LUNAR®-COV19 (ARCT-021) produced a robust antibody response, with a moderate antibody titration increase on the 60th day.
    addition, a single dose of 2 μg and 10 μg of LUNAR®-COV19 completely protects human ACE2 genetically modified mice from death or even measurable infections after wild SARS-CoV-2 attacks.
    the company believes the findings, conducted in collaboration with Duke National University School of Medicine, show the potential of LUNAR®-COV19 as a single-dose vaccine.
    company is currently conducting ® phase 1/2 clinical study of LUNAR-COV19.
    we found that Bioarchive data continued to provide strong ® immunogenicity of LUNAR-COV19.
    results showed that a vaccination in mice produced a strong antibody response, with a moderate antibody titration increasing at the 60th day.
    addition, cell-mediated immune activation produced a strong viral antigen-specific CD8-T lymphocyte response and an ideal Th1 explicit immune response.
    Importantly, in the genetically modified human ACE2 mouse challenge model, a single very low microgram dose of LUNAR®-COV19 vaccination completely prevented SARS-CoV-2 infection and death, no detectable virus in mice vaccinated against LUNAR®-COV19, the New Infectious Diseases Program, Duke-NUS School of Medicine, and the Scientific Advisory Board of the Aturus Vaccine Platform.
    . Pad Chivukula, chief operating officer of Acturus, said his findings highlight the potential of LUNAR®-COV19 as an efficient, low-dose, single-dose vaccine.
    these beneficial characteristics may provide substantial benefits compared to the many vaccine-based drug treatment options being developed.
    believe that this enabling profile can greatly contribute to the mass vaccination campaign needed to control the global COVID-19 pandemic.
    1, on STARR™Technology STARR™ technology platform combines self-replicating RNA with the leading nanoparticle delivery system LUNAR® into a single solution to produce proteins in the human body.
    's versatile ™ technology allows it to produce protective immune responses or drive therapeutic protein expression when it enters cells, potentially preventing or treating a variety of diseases.
    RNA-based preventive vaccine can trigger rapid and long-lasting antigen expression within the host cell, creating protective immunity to infectious pathogens.
    LUNAR® and the combination of STARR™ the technology is expected to provide lower dose requirements because it has a better immune response, continuous protein expression, and the possibility of faster and simpler production of vaccines than non-self-replicating RNA vaccines.
    2, about Artuturus Therapeutics Therapeutics Holdings is a clinical stage mRNA drug and vaccine company with mainly LUNAR® lipid mediated transport, STARR™ messenger RNA technology, MessengerRNA API and Professional knowledge and technology of pharmaceutical production. Arcturus' RNA treatment and vaccine candidates include self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza, as well as other potential treatments for osteoine transaminase (OTC) deficiency, cystic fibrosis, cardiovascular disease, and collaborative projects including glycogen storage disease 3, hepatitis B virus and non-alcoholic fatty hepatitis (NASH).
    Acturus' versatile RNA treatment platform can be used in a variety of nucleic acid drugs, including messenger RNA, small interfering RNA, replicated RNA, antonym RNA, microRNA, DNA, and gene editing therapy.
    Arturus' technology is included in its extensive patent portfolio (192 patents and patent applications issued in the United States, Europe, Japan, China and other countries).
    Acturus is committed to developing new RNA treatment technologies and has collaborated with Janssen Pharmaceuticals, Inc., Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, SyntheticGenomics Inc., Duke NUS, and the Cystic Fibrosis Foundation.
    3, forward-looking statements based on the Company's mRNA therapy, the Company's ongoing phase 1/2 and the availability of expected results, and forward-looking statements regarding the potential of COVID-19 vaccines as single-dose vaccines and the impact of general commercial and economic conditions are forward-looking statements.
    In its Annual Report of December 31, 2012 filed with the U.S. Securities and Exchange Commission (SEC), these uncertainties include "uncertainties as described in the annual report filed by the Securities and Exchange Commission (SEC) as of December 31, 2020" and "these risk factors" are discussed in the annual report filed with the Securities and Exchange Commission as of December 31, 2020.
    references: s.J. Jenepha Mary; Mohd Usman Mohd Siddique; Sayantan Pradhan; Venkatesan Jayaprakash; C. James. Quantum Chemical insight into molecular structure, NBO analysis of thehydrogen-bonded interactions, spectroscopic (FT-IR, FT-Raman), drug likenessand molecular docking of the novel anti COVID-1972-(4,6-diaminopyrimidin-2-yl) sulfanyl- N-(4-fluorophenyl) acetedam-dim. (J). Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.2020. Massimo Candela; Valerio Luconi; Alessio Vecchio. Impact of the COVID-19 pandemic on the Internet latency: Alarge-scale study. Computer Networks.2020. Wallace Woon Fong Leung; Qiangqiang Sun. Electrostatic charged nanofiber filter for filtering airborne novelcoronavirus (COVID-19) and nano-aerosols. Separation and Purification Technology.2020. Nan Wang; Yan Zhan; Linyu Zhu; Zhibing Hou; Feng Liu; Pinhong Song; Feng Qiu; Xiaolin Wang; Xiafei Zou; Deyun Wan; Xiaosong Qian; Shanshan Wang; Yabi Guo; Hao Yu; MiaoCui; Gangling Tong; Yunsheng Xu; Zhihua Zheng; Yinging Lu; Peng Hong. Retrospective Multicenter Cohort Study Show Early Interferon Therapy IsAssociated with Favor Clinical Responses in COVID-19Patients. (J). Cell Host and Microbe.2020. Margaret M. Sugg; Trent J. Spaulding; Sandi J. Lane; Jennifer D. Runkle; Stella R. Harden; Adam Hege; Lakshmi S. Iyer. Mapping community-level determinants of COVID-19 transmissionin nursing homes: A multi-scale approach. Science of The TotalEnvironment.2020. Priyanka Sarkar; Nirmal Debnath; Demsai Reang. Coupled human-environment system amid COVID-19 crisis: Aconceptual model to understand the nexus. Science of The TotalEnvironment.2020. Menachem Ben-Ezra; Shaojing Sun; Wai Kai Hou; Robin Goodwin.The association of being in quarantine and related COVID-19 recommendedand non-recommended behaviors with psychological distress in Chinese population. (J). Journal of Affective Disorders.2020. Miquel A. Fullana; Diego Hidalgo-Mazzei; Eduard Vieta; Joaquim Radua. Coping behaviors associated with developed anxiety and depressivesymptoms when the COVID-19 pandemic and lockdown. Journalof Affective Disorders.2020. Paolo Fusar-Poli; Paolo Brambilla; Marco Solmi. Learning from COVID-19 pandemic in northen italy: Impact onmental health and clinical care. Journal of Affective Disorders.2020. Li Duan; Xiaojun Shao; Yuan Wang; Yinglin Huang; Junxiao Miao; Xueping Yang; Gang Zhu.An investigation of mental health status of children and adityons inchina when the outbreak of COVID-19. Journal of AffectiveDisorders.2020. Peter G. van der Velden; Carlo Contino; Marcel Das; Peter van Loon; Mark W.G. Bosmans. Anxiety and depression symptoms, and lack of emotional support among thegeneral population before and when the COVID-19 pandemic. Aprospective national study on option and ri
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.